A First‐in‐Japanese Phase 1, Double‐Blind, Placebo‐Controlled, Parallel‐Cohort Study of Sefaxersen, an Antisense Oligonucleotide Targeting Complement Factor B, in Healthy Participants
Clinical Pharmacology in Drug Development · 2026
DOI: 10.1002/cpdd.70097 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology in Drug Development, 2026. Verfasst von Takakazu Sato und 3 weiteren Autor:innen. Beteiligte Einrichtung: Chugai Pharmaceutical Co., Ltd., Tokyo, Japan. Hauptthemen laut MEDLINE: Oligonucleotides, Antisense, Complement Factor B, Oligonucleotides. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Chugai Pharmaceutical Co., Ltd.
Abstract (Originalsprache)
Increased activity in the complement alternative pathway (AP) plays a key role in diseases such as IgA nephropathy (IgAN). This first‐in‐Japanese double‐blind Phase 1 study investigated the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of sefaxersen (RO7434656), an antisense oligonucleotide targeting complement factor B messenger RNA. Healthy participants were randomized equally into four cohorts: placebo or sefaxersen 20, 40, or 70 mg. The PK, PD, and safety endpoints were monitored throughout the study and during the 90‐day follow‐up period. All 24 participants completed the study, with no new safety signals or clinically meaningful changes in blood chemistry, electrocardiogram, or vital signs observed. Plasma sefaxersen concentration demonstrated a biphasic PK profile, characterized by an initial rapid decline followed by a slow elimination. Sefaxersen decreased PD markers related to the complement AP selectively, without affecting the classical pathway, in a dose‐dependent manner, and the PD effects persisted over 2 to 3 months. Sefaxersen was well tolerated by healthy Japanese participants, with a manageable safety profile. These findings support the inclusion of Japanese patients with IgAN in the global Phase 3 study (IMAGINATION, NCT05797610).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.
- Clinical Research Hospital, Tokyo, Japan.
Förderung
- Chugai Pharmaceutical Co., Ltd
Zitieren
APA
Sato, T., Fukase, H., Ishida, T., & Karasawa, A. (2026). A First‐in‐Japanese Phase 1, Double‐Blind, Placebo‐Controlled, Parallel‐Cohort Study of Sefaxersen, an Antisense Oligonucleotide Targeting Complement Factor B, in Healthy Participants. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.70097
Vancouver
Sato T, Fukase H, Ishida T, Karasawa A. A First‐in‐Japanese Phase 1, Double‐Blind, Placebo‐Controlled, Parallel‐Cohort Study of Sefaxersen, an Antisense Oligonucleotide Targeting Complement Factor B, in Healthy Participants. Clinical Pharmacology in Drug Development. 2026. doi:10.1002/cpdd.70097
BibTeX
@article{Sato2026,
author = {Sato, Takakazu and Fukase, Hiroyuki and Ishida, Takaaki and Karasawa, Arisa},
title = {A First‐in‐Japanese Phase 1, Double‐Blind, Placebo‐Controlled, Parallel‐Cohort Study of Sefaxersen, an Antisense Oligonucleotide Targeting Complement Factor B, in Healthy Participants},
journal = {Clinical Pharmacology in Drug Development},
year = {2026},
doi = {10.1002/cpdd.70097}
}
EUVIMED